The Food and Drug Administration has rejected ITM Isotope Technologies Munich SE’s radiopharmaceutical therapy ITM-11, citing manufacturing issues in a regulatory letter, according to STAT. The decision was characterized in the article as a surprise and prevents what would have been a competitor to a Novartis therapy from reaching the U.S. market at this time.
STAT reports that the FDA communicated the rejection in a letter; the publicly available portion of the STAT article does not reproduce the full FDA correspondence or enumerate the specific manufacturing deficiencies referenced.
ITM Isotope Technologies Munich is described in the STAT piece as a long-standing company in the radiopharmaceutical sector. The company developed ITM-11 for treatment of gastroenteropancreatic neuroendocrine tumors (GEP‑NETs), a group of relatively rare tumors that emerge in the pancreas, stomach, small intestine, and other parts of the gastrointestinal tract.
The STAT article frames ITM’s program in the broader context of radiopharmaceutical development and competition within oncology, noting that ITM-11 was expected to be a notable rival to an existing Novartis product.
STAT cites ITM’s previously reported clinical data from March 2025. In that report, ITM stated that patients with earlier-stage GEP‑NETs who received ITM-11 infusions experienced a median period of 23.9 months without tumor growth. By comparison, patients treated with everolimus — an established oral therapy — had a median of 14.1 months before disease progression in the comparison provided by ITM and referenced in STAT.
The STAT article does not provide additional trial details in the publicly available excerpt: it does not include full trial design, patient numbers, statistical analyses, regulatory submission dates, or whether the ITM data were from randomized or single-arm cohorts. Those specifics were not reported in the portion of the source article available without a STAT+ subscription.
The source explains radiopharmaceuticals as an emerging therapeutic class that deliver radioactive isotopes directly to tumor cells. This targeted approach is intended to concentrate radiation on malignant tissue while sparing more normal tissue compared with external-beam radiation. The STAT piece situates ITM-11 within this evolving field and references additional STAT coverage on the promise and setbacks encountered by radiopharmaceutical development.
ITM’s program exemplifies the interest in radiopharmaceuticals as potential high‑impact oncology therapies, and the FDA’s scrutiny of manufacturing processes highlights regulatory challenges specific to producing radioactive medicinal products at scale and to the standards required for market authorization.
According to the STAT coverage, the FDA’s rejection halts ITM’s near-term prospects to enter the U.S. market with ITM-11, delaying competition with existing therapies including those from Novartis. The decision underscores regulatory emphasis on manufacturing quality for radiopharmaceuticals and suggests that manufacturing readiness can be a decisive factor in approval even when clinical signals are viewed as promising.
Beyond the immediate commercial and development setbacks for ITM, the article implies broader ramifications for the radiopharmaceutical field: regulatory enforcement around manufacturing could affect other developers and the pace at which novel radiopharmaceuticals become available to patients.
The STAT piece available in the public excerpt is explicit that the full article is exclusive to STAT+ subscribers. As such, several concrete details are not present in the accessible portion of the source article. The following items were not reported in the publicly available text and therefore cannot be restated here:
Readers seeking those specifics would need to consult the full STAT+ article, regulatory filings, or statements from the FDA and ITM. The source identifies Allison DeAngelis as the author and dates the STAT article Aug. 10, 2026.
Conclusion
The STAT report conveys that the FDA rejected ITM-11 on the basis of manufacturing issues, putting on hold a radiopharmaceutical program that had shown a longer median progression-free period in earlier-stage GEP‑NET patients compared with everolimus, as reported by the developer. The publicly accessible portion of the story is limited in technical and procedural detail; the STAT article indicates additional coverage is behind a paywall and does not reproduce the FDA’s letter or ITM’s full response in the available text.